# A Phase III Study of GS101 Injection to Dupixent®

> **NCT07386743** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Jiangsu Genscend Biopharmaceutical Co., Ltd** · enrollment: 572 (estimated)

## Conditions studied

- Atopic Dermatitis (AD)

## Interventions

- **DRUG:** GS101 injection
- **DRUG:** DUPIXENT®

## Key facts

- **NCT ID:** NCT07386743
- **Lead sponsor:** Jiangsu Genscend Biopharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2027-04
- **Final completion:** 2028-01
- **Target enrollment:** 572 (ESTIMATED)
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07386743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07386743, "A Phase III Study of GS101 Injection to Dupixent®". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07386743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*